A Multicenter, Open Label, Comparative Study to Evaluate a Fully Liquid Pentavalent DTwP-HepB-Hib Vaccine (EasyfiveTM, Panacea Biotec Ltd.) with Pentavalent DTwP-HepB/Hib Vaccine (Tritanrix-HBTM Reconstituted With HiberixTM, GSK) in Healthy Infants.
- Registration Number
- CTRI/2012/02/002430
- Lead Sponsor
- Panacea Biotec Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Applicable
- Sex
- Not specified
- Target Recruitment
- 600
1.Infants of 2 months (+2 weeks) of age whose parents/LAR give written informed consent prior to the study entry.
2.Infants with good health as determined by:
• Medical history
• Physical examination
• Clinical judgment of the investigator
3.Infants who are not seroprotected against Diphtheria, tetanus, pertussis, Hepatitis B or H. influenzae type b by virtue of previous immunization and/or antigen exposure. â??Zero doseâ?? of Hepatitis B vaccine will be allowed for subjects who are enrolled in Thailand.
1.The parents or LAR are unwilling or unable to give written informed consent to participate in the study.
2.Infants having history of previous immunization or infection with one of the vaccine constituents. â??Zero doseâ?? of Hepatitis B vaccine will be allowed for subjects who are enrolled in Thailand.
3.Known HBsAg positivity in mother.
4.Presence of evolving or changing neurological disorder.
5.Infants with history of seizures before receiving the vaccine, initiation or continuation of pertussis vaccination should be deferred until an evolving neurological disorder can be excluded.
6.Fever >= 38°C (Axillary temperature >= 37°C) in past 3 days.
7.Any evidence of acute illness or infection requiring systemic antibiotic therapy within past 7 days.
8.Planned or elective surgery during the course of the study.
9.Infants born before the 37th week of gestation.
10.Birth weight less than 2.5 kg.
11.Infants with a known or suspected impairment of the immune function, or those receiving immunosuppressive therapy, or having received immunosuppressive therapy within 1 month prior to study entry (including systemic or inhaled corticosteroids) or those who have received a parenteral immunoglobulin preparation
12.Any history suggestive of thrombocytopenia or a bleeding disorder.
13.Infants who have received any blood products, cytotoxic agents or radiotherapy.
14.Infants with history of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component.
15.Infants with any serious chronic disease such as cardiac, autoimmune disease or insulin dependent diabetes or with any condition that in the opinion of the investigator might interfere with the evaluation of the study objectives.
16.Infants who have participated in another trial of an investigational agent within 30 days of enrolment.
17.Infants whose families are planning to leave the area of the study site before the end of the study period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method â?¢Proportion of subjects achieving seroprotection against diphtheria, tetanus, Hepatitis B and Hib and seroresponsiveness against pertussis, 1 month after three dose vaccination series of DTwP-HB-Hib vaccine in each of the two treatment groups.Timepoint: â?¢Proportion of subjects achieving seroprotection against diphtheria, tetanus, Hepatitis B and Hib and seroresponsiveness against pertussis, 1 month after three dose vaccination series of DTwP-HB-Hib vaccine in each of the two treatment groups.
- Secondary Outcome Measures
Name Time Method